{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Placebo+for+Dapagliflozin&page=2",
    "query": {
      "intervention": "Matching Placebo for Dapagliflozin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Placebo+for+Dapagliflozin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Placebo+for+Dapagliflozin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T16:35:19.033Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03801642",
      "title": "Dapagliflozin In Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jeff Burns, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 46,
      "start_date": "2019-01-29",
      "completion_date": "2022-07-07",
      "has_results": true,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801642"
    },
    {
      "nct_id": "NCT04249778",
      "title": "Dapagliflozin at Discharge on Hospital Heart Failure Readmission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 105,
      "start_date": "2020-07-29",
      "completion_date": "2022-03-03",
      "has_results": true,
      "last_update_posted_date": "2024-06-14",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • New Orleans, Louisiana • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249778"
    },
    {
      "nct_id": "NCT01137474",
      "title": "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo-matching dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 2996,
      "start_date": "2010-07",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2017-01-26",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 164,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01137474"
    },
    {
      "nct_id": "NCT00528879",
      "title": "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 915,
      "start_date": "2007-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 28,
      "location_summary": "Tempe, Arizona • Encino, California • Fresno, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00528879"
    },
    {
      "nct_id": "NCT06268873",
      "title": "A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease and Hypertension"
      ],
      "interventions": [
        {
          "name": "Baxdrostat/dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin in combination with placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2554,
      "start_date": "2024-03-29",
      "completion_date": "2028-02-24",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 114,
      "location_summary": "Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06268873"
    },
    {
      "nct_id": "NCT05570305",
      "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Zibotentan",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin and Zibotentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Medical Center Groningen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-10-06",
      "completion_date": "2025-03-05",
      "has_results": false,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570305"
    },
    {
      "nct_id": "NCT03316131",
      "title": "A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asymptomatic Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "Verinurad",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin matched placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-10-25",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03316131"
    },
    {
      "nct_id": "NCT05516498",
      "title": "Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Part A: zibotentan (dose B) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Part B: placebo (matching zibotentan capsule) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose A) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose B) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose C) + dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 205,
      "start_date": "2022-10-31",
      "completion_date": "2025-07-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05516498"
    },
    {
      "nct_id": "NCT06350123",
      "title": "Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-05-01",
      "completion_date": "2025-05-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 15,
      "location_summary": "Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06350123"
    },
    {
      "nct_id": "NCT02371187",
      "title": "Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Physical Activity"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher Bell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 37,
      "start_date": "2015-06",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-10-10T16:35:19.033Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371187"
    }
  ]
}